Welcome to our dedicated page for Opthea SEC filings (Ticker: CKDXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Opthea's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Opthea's regulatory disclosures and financial reporting.
Opthea Limited (CKDXF) filed its Form 20-F describing a company without product revenues that continues development of biologic candidates including sozinibercept and OPT-302. Management disclosed that it has not obtained regulatory approval for any product candidate, has incurred significant losses, and expects to need additional capital to complete clinical development. The company may reformulate candidates to target VEGF-C/D; if reformulation is not viable directors may consider a return of capital and ceasing operations.
The report discloses a resolution of the Development Funding Agreement: DFA investors provided US$20.0 million and were issued equity equal to 9.99% fully diluted (136,661,003 ordinary shares), liens were released and the DFA terminated. As of August 30, 2025 the Group had US$19.3 million of cash and cash equivalents. Management concluded internal control over financial reporting was not effective as of June 30, 2025 due to errors in accounting for the Funding Agreement and investor options.
